Blum Robert I 4

What Happened
Robert I. Blum, President & CEO and a director of Cytokinetics, reported a sale of 7,500 shares on 2026-04-01. The shares were disposed at $66.63 per share for total proceeds of $499,725. The transaction is reported as an open-market or private sale (code S), i.e., a sale of common stock rather than an options exercise or award.

Key Details

• Transaction date: 2026-04-01; Price: $66.63 per share; Shares sold: 7,500; Proceeds: $499,725.
• Transaction type/code: Sale (S) — reported as "Open market or private sale."
• Shares owned after transaction: Not specified in this Form 4 filing.
• Footnotes: F1 — shares held by The Bridget Blum 2003 Irrevocable Trust; F2 — shares held by The Brittany Blum 2003 Irrevocable Trust.
• Filing date/accession: Form filed 2026-04-01 (no late filing indicated in the record).

Context
Insider sales are common and can be for many personal or financial reasons; they do not by themselves indicate a change in company outlook. This report does not involve option exercise, award grant, or a gift — it is a straightforward reported sale of stock by the CEO.